Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Nothing has changed as far as I know regarding Thales, it is still the manufacture choice and they are targeting 8 systems a year...the 8 systems are reiterated in the recent Corporate Video.
The Daresbury site is just the testing site which I presume was chosen as both a practical solution rather than Geneva and to assist in regulatory approval. I note components are going to be installed there next month and they are working to a very tight schedule!
News flow I expect to continue as the proton speed increases, Dareburys & Harley Street progress & the 2nd Birmingham order is confirmed. Anything else would be a bonus, especially any pre-orders.
Further I am hoping we have an updated Hardman & Co research note soon in which perhaps the target price will be similar or higher than GPSL.
I really do not think this was the case at all....someone IMO was a forced seller, it happens all the time for various reasons. As it happens I benefited hugely like I hope many others who know this company very well. As mentioned yesterday I expect this to be in the 60-70p range based on all the news recently and endorsed significantly today.
I now expect to see a research note imminently from Hardman & Co. Onwards and upwards GLA.
“AVO can well take the entire growth from its cyclotron competitors, which will become an obsolete technology by 2023E”,
“The investment proposition is highly attractive at this stage. We strongly maintain and reiterate both our OUTPERFORM recommendation and TP of 155 GBp.”
http://www.lse.co.uk/share-regulatory-news.asp?shareprice=AVO&ArticleCode=spcx1qjd&ArticleHeadline=GPSL_Research__Flash_Note_on_AVO
All looking good!
"Discussions with potential customers are now multiplying and we expect them to accelerate as we are getting closer to the next phases of our journey. We look forward to having all our accelerating units manufactured to generate a beam at full energy by the middle of next year and start the installation of the system in Harley Street when the building is ready by mid next year.”
https://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xompdmr
Great news!
What ever it is this is getting concerning.....I simply do not understand why this is declining so much based on such positive news, the company is simply in a completely different place than anytime this year yet we are now well below the low YTD. I really expected this share to be closr to 60-70p now. I guess it is a waiting game but there will be a number of very concerned shareholders watching the shares tank like this.
Thank you big seller! We all have reasons and I wish them well.
Great opportunity for me to top up several times on the way down....No doubt IMO where this share is going with such good backers and expertise. As the technical update on 27th Sept said " A further technical update will be provided in the next few days", we are now almost 2 weeks since that announcement. Plus the Chairman reiterated in the Half Year Report on 28th Sept "I look forward to updating the market with positive news very soon." I am therefore expecting more good news imminently plus perhaps some clarification on the companies funding strategy which I truly believe has been misinterpreted in the short term as being via a further placing.
I suspect many selling are following the chart and will buy in again on the turn, patience IMO will be rewarded and I am 100% confident in the BOD.
Yes thanks PM44 you have accurately highlighted this does not say "a placing"....Keep up the good work
Quite right "This will involve further funding" does not imply a further placing at all. The Half Year report clearly states "provides a better position and security to pursue longer-term financing options."
The company IMO will want to now increase shareholder value and in particular those that have recently taken part in a placing at 0.49p. The company also IMO is much stronger now, de-risked significantly and in a much better position to negotiate long term loans to complete production and installation of the first LIGHT sytem in Harley Street which is all on track. GLA
The shares were way oversold....somehow it has been assumed there will be another placing. I read the RNS completely differently in that they are now debt free and " The additional funding we have received has contributed to de-risk the business model and provides a better position and security to pursue longer-term financing options." I have been topping up....IMO I do not believe there will be any further placings for some time.
https://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/x8ne3ox
There we go a great report:
Harley Street site building work on schedule, first patient treatment expected by the second half of 2020
Discussions for a second UK site in Birmingham are ongoing, and we remain in discussions regarding the installation
of our LIGHT system, once fully developed, in sites in the USA and others across in Europe, Asia and the Middle
East.
http://www.proactiveinvestors.co.uk/companies/news/205817/advanced-oncotherapy-passes-key-technological-milestone-205817.html
“A further technical update will be provided in the next few days,” the company said.
With all the expected news flow and imminent Half Year Report it will surely give this share momentum.
I would expect based on last years timing we will also have the Half Year Report tomorrow, this is sure to be followed by updated analyst research reports. This will IMO increase gradually, now just clearing the current profit takers and I would fully hope to see circa 50-60p in a few days.
Looking at the Technological Update illustrations / Photos Harley Street also looks to be progressing very well!
https://www.avoplc.com/Portals/0/Documents/Case%20Study%20Periocular%20Tumour%20Plan%20v1.pdf
continues.......reduced treatment related side effects.
Having reached this milestone on schedule the development team are now focussed on the relatively low-execution risk activity of adding further accelerating modules with the objective of treating all indications suitable for proton therapy. A further technical update will be provided in the next few days.
Commenting, Nicolas Sérandour, CEO of Advanced Oncotherapy, said: “We are delighted to have achieved this key milestone in the development of our first LIGHT system. I am also very proud of our team and thankful for their dedication in achieving this milestone. This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients. This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators.”
ADVANCED ONCOTHERAPY PLC
(“Advanced Oncotherapy” or the “Company”)
Technological update
Key technological milestone completed on schedule
LIGHT system now generating proton beams with energies required to treat superficial tumours
Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, provides an update on the technological development of its LIGHT system.
The Company announces that it has reached a key milestone in the development of its next-generation proton therapy technology, the LIGHT system. The first system under development at the Company’s testing facility at CERN, Geneva is now generating a proton beam with sufficient energy required for treating some superficial tumours.
Superficial tumours include ocular tumours, parotid gland tumours, basal cell carcinoma, and some soft tissue sarcomas, to name a few. A specific type of basal cell carcinoma, known as periocular tumours, was modelled for the purpose of establishing the treatment plan based on the data and the proton acceleration reached with the LIGHT system. Periocular tumours are challenging to treat because of their proximity to the eye. Protons may offer an advantage for these patients by largely sparing the eyes and eye lenses from radiation dose.
The resulting plan is available on the website of the company and ‑ based on the proton acceleration generated ‑ shows that:
· The current LIGHT system comfortably covers the simulated clinical case, as well as some marginally deeper tumours
· The healthy tissue ‑ such as the eye and the lens ‑ is dramatically spared from radiation dose with a steep decrease of the radiation levels directly next to the tumour site
· The lens dose is well controlled and the radiation dose around the optic nerve is near zero
The Treatment Planning Software (“TPS”) used in the LIGHT system has been developed by AVO’s partner, RaySearch AB and will be further tailored to include LIGHT system’s many advanced features for AVO’s proprietary use.
The LIGHT system is designed to elicit significant advantages over existing proton therapy technology, such as a higher beam precision and targeting which results in a more conformal dose and greater adjustability at source. Furthermore, the accelerator varies the beam energy actively and therefore significantly reduces undesired secondary radiation seen in traditional proton therapy systems. This ‑ together with the modular design of the LIGHT system ‑ result in thinner radiation shielding next to the accelerator and a smaller foot-print. This makes the LIGHT systems easier and cheaper to operate and install in city-centre locations as compared to systems currently on the market. Taken altogether, these features make the LIGHT system the ideal tool for making proton therapy systems more widely available, with a technology expected to be capable of providing improved outcomes and reduced treatment related